Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 81,837 |
|
|||||
| News | - | ||||||
| Day High | 20.25 | Low High |
|||||
| Day Low | 19.16 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ArriVent BioPharma Inc | AVBP | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.05 | -0.26% | 19.41 | 17:30:01 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 19.85 | 19.16 | 20.25 | 19.41 | 19.46 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 863 | 81,837 | $ 19.75 | $ 1,615,977 | - | 14.35 - 25.5076 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:04:30 | 13 | $ 19.41 | USD |
ArriVent BioPharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 629.23M | 31.96M | - | 0 | -69.33M | -2.17 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ArriVent BioPharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVBP Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 18.90 | 20.25 | 18.11 | 19.18 | 49,231 | 0.51 | 2.70% |
| 1 Month | 16.99 | 21.00 | 16.76 | 18.93 | 42,636 | 2.42 | 14.24% |
| 3 Months | 20.06 | 21.00 | 14.35 | 18.04 | 147,189 | -0.65 | -3.24% |
| 6 Months | 24.00 | 25.5076 | 14.35 | 19.19 | 171,828 | -4.59 | -19.13% |
| 1 Year | 24.00 | 25.5076 | 14.35 | 19.19 | 171,828 | -4.59 | -19.13% |
| 3 Years | 24.00 | 25.5076 | 14.35 | 19.19 | 171,828 | -4.59 | -19.13% |
| 5 Years | 24.00 | 25.5076 | 14.35 | 19.19 | 171,828 | -4.59 | -19.13% |
ArriVent BioPharma Description
| ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. |
